Revolution Medicines, Inc. RVMD R3KPHARMA
Company Overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +474.77% |
| 6 Months: | +107.76% |
| 3 Months: | +39.62% |
| 1 Month: | +1.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. R3KPHARMA | 207.32 | -23.40 | $44.44B | 0.00% | -57.28% | -79.09% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.17M | 12.28M | 12.51M | 12.09M | 11.55M | 10.03M | 12.66M | 8.75M | 10.13M | 8.70M | 1.10M | 7.58M | 9.12M | 3.36M | 7.01M | 3.82M | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 240.76M | 264.71M | 315.27M | 361.63M | 445.22M | - |
| Operating Income | -10.44M | -10.56M | -13.56M | - | -21.08M | -27.98M | -27.55M | - | -37.40M | -44.53M | -53.16M | -57.95M | -62.09M | -76.53M | -75.16M | -108.80M | -123.25M | -140.86M | -156.64M | -175.71M | - | -240.76M | -264.71M | -315.27M | -361.63M | -445.22M | -505.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -237.04M | -260.91M | -289.44M | -348.25M | -437.08M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.43M | 11.94M | 12.20M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -753.00K | - | - | - | - | - | - |
| Net Income | -10.13M | -10.12M | -12.82M | -14.60M | -19.52M | -27.21M | -27.22M | -34.20M | -37.18M | -44.30M | -52.94M | -57.65M | -61.22M | -73.33M | -68.10M | -98.30M | -108.43M | -116.00M | -133.23M | -156.29M | - | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M | -644.37M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.60 | -0.72 | -0.78 | -0.82 | -0.87 | -0.72 | -0.92 | -0.99 | -0.70 | -0.81 | -0.94 | - | -1.13 | -1.31 | -1.61 | -1.86 | -2.29 | -3.06 |
| R&D Expense | 21.19M | 20.12M | 22.96M | - | 27.46M | 32.92M | 34.87M | - | 40.86M | 45.94M | 46.47M | 56.49M | 61.00M | 69.45M | 68.95M | 97.98M | 107.73M | 118.02M | 134.93M | 151.75M | - | 205.75M | 224.13M | 262.51M | - | 343.97M | 394.92M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.16M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 293.66M | 498.76M | 689.52M | 1.18B |
| Operating Income | -40.33M | -54.12M | -110.70M | -188.01M | -258.28M | -487.19M | -689.52M | -1.18B |
| EBITDA | - | - | - | - | -248.62M | -430.58M | -589.02M | -1.09B |
| Interest Expense | - | - | - | - | 0 | 0 | 0 | 24.23M |
| Pretax Income | - | - | - | - | -249.12M | -439.89M | -600.85M | -1.13B |
| Tax Provision | - | - | - | - | -420.00K | -3.52M | -753.00K | 0 |
| Net Income | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B |
| Diluted EPS | - | - | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |
| R&D Expense | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M | 987.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 220.53M | 567.40M | - | 811.93M | 2.06B | 2.56B | 2.35B |
| Current Assets | - | - | - | - | - | 660.18M | 1.88B | 2.33B | 2.08B |
| Cash & Equivalents | - | 69.59M | 16.66M | 104.27M | - | 161.41M | 696.15M | 543.06M | 383.75M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 5.93M | 4.67M | 1.25M | 0 | - |
| Total Liabilities | - | - | 67.99M | 92.72M | - | 126.74M | 235.51M | 293.10M | 723.21M |
| Current Liabilities | - | - | 43.05M | 47.18M | - | 61.98M | 143.85M | 163.91M | 290.42M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 64.20M | 87.94M | 135.84M | 158.70M |
| Total Equity | -67.72M | -108.42M | -152.57M | 474.68M | - | 685.19M | 1.83B | 2.27B | 1.63B |
| Shares Outstanding | - | - | - | - | - | 90.41M | 164.67M | 185.90M | 197.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.21M | -49.62M | -100.06M | - | -224.40M | -350.57M | -557.44M | -897.74M |
| Investing Cash Flow | -1.34M | -101.97M | -234.23M | - | -24.12M | -342.60M | -554.39M | 118.06M |
| Financing Cash Flow | 60.85M | 98.66M | 422.78M | - | 301.43M | 1.23B | 959.41M | 621.52M |
| Capital Expenditure | -1.50M | -2.59M | -2.93M | - | -10.82M | -7.73M | -10.31M | -15.99M |
| Free Cash Flow | -286.00K | -52.20M | -103.00M | - | -235.22M | -358.30M | -567.74M | -913.73M |
| Net Change in Cash | - | - | - | - | 52.91M | 536.03M | -152.42M | -158.16M |
| Dividends Paid | - | - | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -200.0% | -108.2% | -257.5% | -639.7% | -730.0% | -4,207.1% | - | - |
| Net Margin % | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3,768.3% | - | - |
| ROE % | 38.5% | 31.2% | -22.8% | - | -36.3% | -23.9% | -26.5% | -69.3% |
| ROCE % | - | -30.5% | -21.3% | - | -34.4% | -25.4% | -28.8% | -57.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.39% | 13.70M | $2.62B |
| 2 | Farallon Capital Management LLC | 6.32% | 13.55M | $2.59B |
| 3 | FMR, LLC | 5.69% | 12.20M | $2.33B |
| 4 | Baker Bros. Advisors, LP | 5.34% | 11.44M | $2.19B |
| 5 | Jupiter Topco LLC | 5.01% | 10.74M | $2.05B |
| 6 | Darwin Global Management, Ltd. | 4.96% | 10.63M | $2.03B |
| 7 | Vanguard Capital Management LLC | 4.24% | 9.09M | $1.74B |
| 8 | Vanguard Portfolio Management LLC | 3.87% | 8.29M | $1.58B |
| 9 | Nextech Invest, Ltd. | 3.55% | 7.60M | $1.45B |
| 10 | Paradigm Biocapital Advisors LP | 2.97% | 6.36M | $1.21B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RVMD
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOZzA3ZzhvMlVzMkpUS3BaQUI1UlNSMmxYTlE5cXlwZzJrbVl4c29Eblllb1pQZ3RwVEQzVXN1UmtCR183b29IWGVfR0ZHSUVKeDJCWEV3dW85UWxyV2JjS09TR3pzMmVEdzQ0WVlSemdUSkZDVy1Ba3lfQTNLZGQ5OE1nRFEwcElaU05abD…
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNWJfY0pRV2xTel9na3U1Ulk4dGFNSFB2enlYdURjdTEyMlBjZWtDdEZqSTF3YTdjM05ILWdheUZ1c0JSOGF3c3ZUMDJWY0RKRmpFYWZNQU5PNmp4RWlqM2NKTEY0WVpkYTZmOXphcnNPYTdvaHdHWW5CdEJ0ZjBFbkJZTXZZcUViQXQ3cm…
Revolution Medicines Got Its Breakthrough—What Moves It Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPY1NWMTdEc0ZwZHVlMUpndURIN0ROOEJTbjMzZTZDRV9yRnhLdTJvd1BVcmc2VzJ4Z0JGRmVsNHN0MUZ6a1Y0UFBxTmlVczlHNUk1d214Ty1jcl8wczJZc0ZOaVF3NDFmdUZ4N3haWlVqOFg1Zi05Q3lQdzgxNUdVV3gyTms3aHhGUkV4Zm…
Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPeTU5ZGtHMUdocVRsNE9EVUJ6QXVzUmRBU2tGTWNtNnI4d0dBZGlLdUhRUXZ6ZGI0Zl9BM0pBdXJGUVJGTjlyUkJzN2M1X0R3djY1ZmZlVHh4QTFvZll6amQzTTNvZlRyTkE0eW1LNndyVWNWdG5qZUxkSjN6Z29SZk4tVUdOc1diVy1KcF…
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVmlJMW4xR25zRXF2dXpxZ2FIVEZmd184dE9tSC1SMzVxZnJWRkZ1YzFnLWhnUlRiRkxNUVM4aUF2aTAxRi1KdHhGVUpucFpSenZET3U2OW02QkF6Z080R1NDOEs2dFBiejVXd1VsbnB3Z1V2RmVIYXNEZWtXVkYydVlzd2tBSDh6N0w3Zj…
RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill — Is Drug Price Overshadowing Approval? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxQNm4zcnNHVmIycVo3NGl6N3hkTmU2b1RzSUFMUUdCN2c5V09WeEw3ZW9yanQxWng5Tml6Zm44SENnNGxlSmtMNjQ5UTFIRjJULWtIUno3WExwNTZuczNlRnppMzhnNm5FOThGazNmZFlSZnFpaTVhODE0U2pHVUVOVDNvWkRfdkVQbGM4T0…
RVMD — Frequently Asked Questions
What is the current share price of Revolution Medicines, Inc. (RVMD)?
As of 2026-09-19 21:16 PDT, Revolution Medicines, Inc. (RVMD) trades at $207.32 on NasdaqGS. Its 52-week range is $35.67 to $221.15.
What is the market capitalisation of RVMD?
Revolution Medicines, Inc. (RVMD) has a market capitalisation of $44.44B on NasdaqGS.
What is the P/E ratio of RVMD?
RVMD trades at a trailing price-to-earnings (P/E) ratio of -23.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 25.48.
What is the return on equity (ROE) of RVMD?
RVMD has a return on equity (ROE) of -79.09%. Its return on capital employed (ROCE) is -57.28%.
Is RVMD a good stock to buy?
This page provides a data-driven analysis of Revolution Medicines, Inc. (RVMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.